Volume 89 Issue 13 | p. 23 | Concentrates
Issue Date: March 28, 2011

Lonza Inks Biologic Manufacturing Pacts

Department: Business
Keywords: drug discovery, manufacturing, contract services
[+]Enlarge
Lonza will manufacture Enobia’s drug at its Portsmouth, N.H., site.
Credit: Lonza
8913busconlonza_live-2
 
Lonza will manufacture Enobia’s drug at its Portsmouth, N.H., site.
Credit: Lonza

Lonza has signed a drug development and manufacturing agreement with Athera Biotechnologies, part of Sweden’s Karolinska Development. Under the agreement, the Swiss contract services company will initiate cell-line and process development for Athera’s monoclonal antibody, PC-mAb, intended for the treatment of patients with acute coronary syndrome. Lonza has also signed an agreement with Enobia for the development of the Montreal firm’s enzyme replacement therapy ENG-0040, which has completed Phase II trials for juvenile rickets.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment